Skip to main content
SpringerLink
Log in

Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) are common subtypes of T-cell lymphoma. Although CHOP is a standard regimen for T-cell lymphoma, it has unsatisfactory outcomes. Pirarubicin is an anthracycline antibiotic with lower cardiotoxicity than doxorubicin. THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisone) is sometimes used for elderly patients with non-Hodgkin’s lymphoma in Japan. We performed a retrospective analysis using data from the population-based Osaka Cancer Registry as well as administrative data from 2010 to 2015. Of 82 enrolled patients, 51 received CHOP and 31 received THP-COP. The median age was 65 years in the CHOP group and 75 years in the THP-COP group. The probability of 3-year overall survival (OS) was 49.0% in the CHOP group and 44.9% in the THP-COP group. In the propensity score-adjusted analysis, there was no significant difference between the THP-COP and CHOP groups in the OS of the total sample [hazard ratio (HR) 0.46, 95% CI 0.14–1.55, P = 0.2]. Although our study was limited by its retrospective nature, it showed that clinical outcomes with the THP-COP regimen were comparable to those with the CHOP regimen in PTCL-NOS and AITL. Our findings should be re-assessed in larger studies in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

    Article  CAS  Google Scholar 

  2. Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89(11):3909–18.

    Google Scholar 

  3. Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, et al. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot. 1979;32(10):1082–4.

    Article  CAS  Google Scholar 

  4. Kunimoto S, Miura K, Umezawa K, Xu C-Z, Masuda T, Takeuchi T, et al. Cellular uptake and efflux and cytostatic activity of 4′-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines. J Antibiot. 1984;37(12):1697–702.

    Article  CAS  Google Scholar 

  5. Imura H, Ito N, Shirakawa S, Sobue R, Maruyama F, Kojima H, et al. THP-COP, BHAC-VMP alternating chemotherapy in patients with non-Hodgkin’s lymphoma. Rinsho Ketsueki. 1988;29(5):688–93.

    CAS  PubMed  Google Scholar 

  6. Shibata Y, Hara T, Kasahara S, Yamada T, Sawada M, Mabuchi R, et al. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin. Hematol Oncol. 2017;35(2):163–71.

    Article  CAS  Google Scholar 

  7. Niitsu N, Umeda M. Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM. Eur J Haematol. 1999;63(5):337–44.

    Article  CAS  Google Scholar 

  8. Mori M, Kitamura K, Masuda M, Hotta T, Miyazaki T, Miura AB, et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin’s lymphoma. Int J Hematol. 2005;81(3):246–54.

    Article  CAS  Google Scholar 

  9. Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, et al. THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study. Eur J Haematol. 2010;84(5):391–7.

    Article  Google Scholar 

  10. Tomita N, Kodama F, Tsuyama N, Sakata S, Takeuchi K, Ishibashi D, et al. Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients. Hematol Oncol. 2015;33(1):9–14.

    Article  CAS  Google Scholar 

  11. Fuji S, Kida S, Morishima T, Nakata K, Miyashiro I, Ishikawa J. Clinical outcomes of patients with adult T Cell leukemia-lymphoma in a nonendemic metropolitan area: a retrospective analysis of the population-based Osaka cancer registry. Biol Blood Marrow Transplant. 2020;26(8):1433–8.

    Article  CAS  Google Scholar 

  12. Morishima T, Matsumoto Y, Koeda N, Shimada H, Maruhama T, Matsuki D, et al. Impact of comorbidities on survival in gastric, colorectal, and lung cancer patients. J Epidemiol. 2019;29(3):110–5.

    Article  Google Scholar 

  13. Shigemi D MT, Shibata A, Tabuchi T, Yasunaga H, Miyashiro I. Comparison of overall mortality between hysterectomy and concurrent chemoradiotherapy for the primary treatment of localized or regionally extended cervical cancer. Annals of clinical epidemiology. In press.

  14. Morishima T SA, Nakata K, Miyashiro I. Geriatric assessment domains to predict overall survival in older cancer patients: an analysis of functional status, comorbidities, and nutritional status as prognostic factors. Cancer Medicine. In press.

  15. Miyamoto Y, Ohbe H, Ishimaru M, Matsui H, Fushimi K, Yasunaga H. The effect of carbazochrome sodium sulfonate in patients with colonic diverticular bleeding: propensity score matching analyses using a Nationwide inpatient database. Inter Med. 2020;59(15):1789–94.

    Article  CAS  Google Scholar 

  16. International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–94.

    Article  Google Scholar 

  17. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–9.

    Article  CAS  Google Scholar 

  18. Mourad N, Mounier N, Brière J, Raffoux E, Delmer A, Feller A, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111(9):4463–70.

    Article  CAS  Google Scholar 

  19. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.

    Article  CAS  Google Scholar 

  20. Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–7.

    Article  CAS  Google Scholar 

  21. Cederleuf H, Bjerregård Pedersen M, Jerkeman M, Relander T, d’Amore F, Ellin F. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic Lymphoma Group study. Br J Haematol. 2017;178(5):739–46.

    Article  CAS  Google Scholar 

  22. Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, et al. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol. 2019;98(8):1961–72.

    Article  CAS  Google Scholar 

  23. Shichijo T. Hematopoietic stem cell transplantation for T-cell lymphoma. Adv Cell Gene Ther. 2018;1(1):e6.

    Article  Google Scholar 

  24. Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30.

    Article  Google Scholar 

  25. Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–40.

    Article  CAS  Google Scholar 

Download references

Funding

This research was partially supported by a Health, Labor, and Welfare Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan (H30-Gantaisaku-ippan-009).

Author information

Authors and Affiliations

  1. Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka-shi, Osaka, 5418567, Japan

    Shuhei Kida, Shigeo Fuji & Jun Ishikawa

  2. Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan

    Toshitaka Morishima, Kayo Nakata & Isao Miyashiro

Authors
  1. Shuhei Kida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigeo Fuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toshitaka Morishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kayo Nakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Isao Miyashiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigeo Fuji.

Ethics declarations

Conflict of interest

There are no conflict of interest to declare.

Ethical approval

The study was approved by the institutional review board of the Osaka International Cancer Institute in Osaka, Japan (No. 19088).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kida, S., Fuji, S., Morishima, T. et al. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry. Int J Hematol 114, 246–251 (2021). https://doi.org/10.1007/s12185-021-03150-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-021-03150-6

Keywords

Search

Navigation